Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[212Pb]Pb-AG1206
- Development stage
- Unknown
- Lead developer
- AlphaGen Therapeutics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[212Pb]Pb-AG1206 is an investigational targeted alpha therapy (TAT) radiopharmaceutical consisting of the alpha-emitting radioisotope Lead-212 ([212Pb]) conjugated to AG1206, a small molecule ligand with high affinity for Prostate-Specific Membrane Antigen (PSMA). Developed by AlphaGen, this agent is designed to treat metastatic castration-resistant prostate cancer (mCRPC) by delivering high-linear energy transfer (LET) alpha radiation directly to PSMA-expressing tumor cells. Lead-212 serves as an in vivo generator for alpha-emitting progeny, including Bismuth-212 and Polonium-212, which induce lethal double-strand DNA breaks that are difficult for cancer cells to repair. This approach aims to overcome the limitations and resistance associated with beta-emitting radiopharmaceuticals, such as Lutetium-177 based therapies, by providing more potent localized cytotoxicity with minimal damage to surrounding healthy tissue.
- Other names
- Lead-212 AG1206Lead212 AG1206Lead 212 AG1206212Pb-labeled AG1206
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [212Pb]Pb-AG1206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [212Pb]Pb-AG1206.